Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 149 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
How did MOLN's recent EPS compare to expectations?
The most recent EPS for Molecular Partners AG is $-0.23, not beating expectations of $-0.34.
How did Molecular Partners AG MOLN's revenue perform in the last quarter?
Molecular Partners AG revenue for the last quarter is $-0.23
What is the revenue estimate for Molecular Partners AG?
According to of Wall street analyst, the revenue estimate of Molecular Partners AG range from $ to $
What's the earning quality score for Molecular Partners AG?
Molecular Partners AG has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Molecular Partners AG report earnings?
Molecular Partners AG next earnings report is expected in 2026-06-10
What are Molecular Partners AG's expected earnings?
Molecular Partners AG expected earnings is $0.0, according to wall-street analysts.
Did Molecular Partners AG beat earnings expectations?
Molecular Partners AG recent earnings of $0.0 does not beat expectations.